< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
No significant interference observed with available related molecules.
The Quantikine Human HTRA2/Omi Immunoassay is a 4.5 hour solid phase ELISA designed to measureHTRA2 levels in cell culture supernates, serum, and platelet-poor plasma. It contains E. coil-expressed recombinant human HTRA2
and antibodies raised against the recombinant protein. Results obtained
for naturally occurring human HTRA2 and recombinant human HTRA2
showed linear curves that were parallel to the standard curves obtained
using the Quantikine Human HTRA2/Omi Immunoassay standards. These results
indicate that this kit can be used to determine relative mass values for
natural human HTRA2.
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of a known concentration were tested in twenty separate
assays to assess inter-assay precision. Assays were performed by at
least three technicians using two lots of kit components.
The recovery of human VEGF spiked to levels throughout the range of the assay in various matrices was evaluated.
Average % Recovery
Cell Culture Media (n=4)
Platelet-poor EDTA Plasma (n=4)
Platelet-poor Heparin Plasma (n=4)
To assess the linearity of the assay, samples containing and/or spiked with high
concentrations of HTRA2 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic
range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
HTRA2/Omi is the mammalian homolog of the bacterial high temperature requirement protein (HTRA). HTRA2/Omi is a homotrimeric serine protease that localizes to the mitochondria and is processed to expose an N-terminal reaper-like motif similar to SMAC/Diablo. HTRA2/Omi is released from the mitochondria in response to apoptotic insult and can interact with the BIR2 or BIR3 domains of XIAP to relieve caspase-IAP inhibition.